Developer of medicines derived from the immune responses of insects. The company develops medicines targeting life-threatening infections of both fungal and bacterial origin that have become resistant to existing antibiotics and antifungal drugs. The company has identified biologically important classes of peptides and small molecules, and has purified and characterised hundreds of antimicrobial compounds that have a broad spectrum of activity against fungi and bacteria. The company has also developed inhouse cancer screening capabilities.
Missing: EntoMed's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: EntoMed's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
EntoMed Frequently Asked Questions (FAQ)
When was EntoMed founded?
EntoMed was founded in 1999.
Where is EntoMed's headquarters?
EntoMed's headquarters is located at Rue Tobias Simmer, Illkirch-Graffenstaden.
What is EntoMed's latest funding round?
EntoMed's latest funding round is Secondary Market.
How much did EntoMed raise?
EntoMed raised a total of $21.85M.
Who are the investors of EntoMed?
Investors of EntoMed include Omega Funds, Oxford Bioscience Partners, Atlas Venture, Innovation Capital and Aventis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.